Natera, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Natera (NTRA) and Angiex, a private biotech firm, are collaborating to use Natera's Signatera test for ctDNA monitoring in Angiex's Phase I trial of AGX101, a therapy for solid tumors. The test aims to assess treatment response. NTRA's stock closed at $338.45, up 0.52%.
Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.
Stanley Druckenmiller's Duquesne Family Office has a 16.6% stake in Natera (NTRA), up 37% YTD. Natera's Q2 2026 revenue rose 37.7% YoY to $752.8M, with improved margins and raised guidance. The stock's rally follows regulatory approvals and strong earnings, but high valuation and insider selling raise concerns.
Over the past 7 days, alphai's AI scored 2 news stories mentioning NTRA (Natera, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent NTRA coverage spans financial news, technology and earnings.
In the last 30 days, NTRA insiders filed 33 SEC Form 4 transactions — no purchases and 33 sales ($8.3M). The most active reporter was Sheena Jonathan with 12 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential boost to Natera's test adoption and revenue from oncology trials.
Institutional conviction may signal upside potential for Natera.
Strong earnings and raised guidance may support further price appreciation.
The article frames Natera’s MRD assay adoption as accelerating via a new Kupando collaboration and regulatory progress, anchored by raised revenue guidance.
Insider selling under a 10b5-1 plan is typically lower-signal, but it can still add near-term overhang sentiment after a strong run.
alphai scores every news story that mentions NTRA with an AI model for sentiment and relevance, and aggregates insider trades from Natera, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Natera (NTRA) and Angiex, a private biotech firm, are collaborating to use Natera's Signatera test for ctDNA monitoring in Angiex's Phase I trial of AGX101, a therapy for solid tumors. The test aims to assess treatment response. NTRA's stock closed at $338.45, up 0.52%.
1 min readBillionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.
2 min readStanley Druckenmiller's Duquesne Family Office has a 16.6% stake in Natera (NTRA), up 37% YTD. Natera's Q2 2026 revenue rose 37.7% YoY to $752.8M, with improved margins and raised guidance. The stock's rally follows regulatory approvals and strong earnings, but high valuation and insider selling raise concerns.
2 min readSimply Wall St says Natera (NTRA) is expanding its MRD role in oncology. It cites Kupando Therapeutics’ Phase 1 trial using Natera’s Latitude ctDNA assay, and Natera’s Q2 2026 revenue of $752.75M with net loss of $66.97M. The article notes raised 2026 revenue guidance to $2.85–2.91B and a PMDA submission for Signatera.
6 min readNatera Inc. (NASDAQ:NTRA) executive chairman Matthew Rabinowitz sold 2,000 shares on Aug. 7, 2026 for about $641,800 at $320.9 per share under a Rule 10b5-1 plan adopted Dec. 5, 2025. Afterward, he directly owned 2,275,394 shares. The article also cites Natera’s Q2 revenue of about $753M vs $661.26M forecast and raised full-year guidance.
2 min readSheena Jonathan sold 6,000 shares of Natera, Inc. (NTRA) at $325.32 ($1.95M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min readNatera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.
6 min readNatera (NASDAQ: NTRA) said it will support a Phase 1 trial in Germany for Kupando Therapeutics’ KUP-101 immunotherapy. Natera’s Latitude ctDNA MRD assay will be used at multiple timepoints to monitor treatment response via circulating tumor DNA dynamics. After dosing the first patient, Kupando approved further enrollment at activated sites.
2 min readNatera reported strong Q2 results tied to its Signatera molecular residual disease testing. Volume rose about 56% to 283,000 units, lifting revenue about 38% to $753 million, and the company raised guidance by $100 million. The article also notes an insider sale by executive Moshkevich tied to tax withholding on vested shares.
6 min readNatera CFO Michael Burkes Brophy sold 795 shares at about $271.74 per share on Aug. 3-4 via a non-discretionary sell-to-cover plan for tax obligations after equity vesting, per an SEC Form 4. Natera reported Q2 revenue up 38% to $753 million and raised full-year guidance by $100 million, according to the company.
6 min read
